- Home
- CLM vs APLS Comparison
CLM vs APLS Comparison
Compare CLM & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLM
- APLS
- Stock Information
- Founded
- CLM 1987
- APLS 2009
- Country
- CLM United States
- APLS United States
- Employees
- CLM N/A
- APLS N/A
- Industry
- CLM Finance/Investors Services
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- CLM Finance
- APLS Health Care
- Exchange
- CLM Nasdaq
- APLS Nasdaq
- Market Cap
- CLM 2.0B
- APLS 2.2B
- IPO Year
- CLM N/A
- APLS 2017
- Fundamental
- Price
- CLM $8.11
- APLS $18.75
- Analyst Decision
- CLM
- APLS Buy
- Analyst Count
- CLM 0
- APLS 19
- Target Price
- CLM N/A
- APLS $37.61
- AVG Volume (30 Days)
- CLM 1.4M
- APLS 2.1M
- Earning Date
- CLM 01-01-0001
- APLS 07-31-2025
- Dividend Yield
- CLM 18.74%
- APLS N/A
- EPS Growth
- CLM N/A
- APLS N/A
- EPS
- CLM N/A
- APLS N/A
- Revenue
- CLM N/A
- APLS $775,839,000.00
- Revenue This Year
- CLM N/A
- APLS $8.00
- Revenue Next Year
- CLM N/A
- APLS $13.82
- P/E Ratio
- CLM N/A
- APLS N/A
- Revenue Growth
- CLM N/A
- APLS 48.04
- 52 Week Low
- CLM $6.25
- APLS $16.10
- 52 Week High
- CLM $8.84
- APLS $41.94
- Technical
- Relative Strength Index (RSI)
- CLM 55.55
- APLS 47.23
- Support Level
- CLM $7.92
- APLS $19.16
- Resistance Level
- CLM $8.20
- APLS $20.40
- Average True Range (ATR)
- CLM 0.07
- APLS 0.95
- MACD
- CLM -0.02
- APLS -0.02
- Stochastic Oscillator
- CLM 52.78
- APLS 26.82
About CLM Cornerstone Strategic Value Fund Inc. New
Cornerstone Strategic Value Fund Inc is a closed-end management investment company. The fund's objective is to seek long-term capital appreciation through investments in equity securities of U.S. and non-U.S. companies. It invests in various sectors, which include financials, information technology, healthcare, consumer discretionary, industrials, utilities, energy, telecommunication services, materials, and other sectors.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.